News
06-15-2005
Curasan Increases its Lead with New Clinical Data
Kleinostheim , Germany , 15th June, 2005 – Cerasorb® synthetic bone regeneration material, produced by curasan AG, equals autogenous bone where therapy is concerned. This is the result of a prospective, randomised multi-centre study headed by Professor György Szabó, Budapest , Hungary and recently published in the renowned Journal of Oral and Maxillofacial Implants (JOMI, Vol. 20, 371-381, June 2005).
To date, widely undifferentiated clinical experience has been gained with the vast range of bone augmentation materials stemming from various sources (bodies, animals, synthetic). This is the reason for which users have long demanded clinical studies comparing these materials directly with autogenous bone from patients, the so-called „gold standard“. Although bone graft substitutes have been in use for decades, so far competing manufacturers have shied this direct comparison.
Curasan is the first company to publish the desired data from this direct comparison. This two-year split-mouth study involved sinus lifting in 20 patients whereby Cerasorb® was used on one side and autogenous bone on the other. Cerasorb® achieved comparable clinical results. Harvesting autogenous bone often requires reentry surgery, which is stressful for the patient. In addition, Cerasorb® treatment is more economical. In total, this proves that Cerasorb® is superior to the gold standard.
This successful outcome was actually predictable as the materiological assets of this product have been documented many times. Amongst other things, Cerasorb® was recently listed by the ICDD (International Center of Diffraction Data, Pennsylvania, USA) as a reference material for all ß-tricalcium phosphates.
To quote Hans Dieter Rössler, Chairman of the Board „During the first few months of this year, the German dental market declined due to the hesitant launch of health reforms and downward economic trend. This outstanding publication has arrived at just the right moment to promote the anticipated recovery effect and broad internationalisation of our business“.
